At a glance
- Originator DuPont
- Developer Bristol-Myers Squibb
- Class Antipsychotics; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psychotic disorders
Most Recent Events
- 18 Jan 2008 Discontinued - Preclinical for Psychotic disorders in USA (PO)
- 05 Jan 2004 No development reported - Preclinical for Psychotic disorders in USA (unspecified route)
- 23 Apr 2001 New profile